Cooperation and Broader Legal Fight
Continuing Multi-State Litigation
As part of the settlement, Lannett and Bausch agreed to assist in the continuing prosecution of other defendants in the sprawling antitrust case.
Tong also noted that states are pursuing claims against Novartis and its subsidiaries, alleging the company is attempting to shield assets fraudulently to avoid accountability.
The Lannett and Bausch drug price fixing deal follows earlier settlements in the same investigation. Apotex and Heritage previously agreed to resolve claims for a combined $49.1 million.
States and Territories Involved
The jurisdictions participating in Monday’s settlement include Alaska, Arizona, California, Colorado, Connecticut, Delaware, the District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, the U.S. Virgin Islands, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming and Puerto Rico.
The proposed deal now awaits court approval.
As state attorneys general continue to peel back what they describe as layers of coordinated pricing practices, the settlement marks another chapter in a nationwide reckoning over the cost of generic drugs — medicines once marketed as the antidote to high pharmaceutical prices, now at the center of a high-stakes antitrust battle.
